Citations

Clear

4207 citation(s) found for "Chen, Yu".

CSF proteomics related to the neurovascular unit are associated with white matter hyperintensity volumes and cerebral microhemorrhages in autosomal dominant Alzheimer disease
Shen, Yuanyuan , Chen, Charles D., Strain, Jeremy F. , Shirzadi, Zahra , Chen, Gengsheng , Massoumzadeh, Parinaz , Lu, Ruijin , Chhatwal, Jasmeer P. , Perrin, Richard J. , Joseph‐Mathurin, Nelly , Friedrichsen, Karl A. , McCullough, Austin , Gordon, Brian A. , Llibre‐Guerra, Jorge J. , Hassenstab, Jason , Ibanez, Laura , Schultz, Stephanie A. , Morris, John C. , An, Hongyu , Xiong, Chengjie , Klein, Robyn S. , Jack, Clifford R. , Bateman, Randall J. , McDade, Eric , Benzinger, Tammie L.S. , Cruchaga, Carlos

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093619 Get It

AbstractBackgroundAutosomal dominant Alzheimer disease (ADAD) is characterized by genetic mutations affecting the beta‐amyloid (Aß) pathway. However, vascular and immune factors play important roles which are not completely understood. Understanding the function of the neurovascular unit (NVU) comprised of neurons, glial cells, and vasculature, at different disease stages appears ideal to developing and evaluating therapeutics. Omics approaches can inform NVU changes and their disease associations.MethodsCSF proteomic data using the Somalogic® platform was generated from 485 participants in the DIAN study, who also had PiB‐PET and MRI assessing Aß burden, white matter hyperintensity (WMH), and cerebral microhemorrhage (CMH). From previously published AD studies, we identified 33 NVU‐associated proteins with corresponding Somalogic aptamers (Figure 1). We used Principal Component Analysis (PCA) on participants with complete data (n = 262, 166 mutation‐carriers and 96 non‐carriers) to find groups of proteins associated with mutation status and disease stage as measured with estimated year to symptom onset (EYO), PiB‐PET, and clinical status. Linear‐mixed effect models and two‐part zero‐inflated negative binomial mixed models further evaluated the link between significant principal components (PCs) and WMH and CMH, respectively. Models accounted for age, APOE‐e4 status, sex, and education.ResultsThe first ten PCs explained >60% of the variance in NVU‐related protein levels (Figure 2A) with only PC5 (4.8%) associated with mutation*EYO, suggesting relationship with ADAD‐specific disease progression (***p<0.0001, Figure 2B). While asymptomatic PiB‐negative individuals were not significantly different from non‐carriers, asymptomatic PiB‐positive individuals had higher PC5 scores than non‐carriers and symptomatic individuals scored still higher (**p<0.005, ***p<0.0001, Figure 2C). The main proteins composing PC5 were: neurofilament light‐chain, angiopoietin‐2, SMOC1, LRP1, E‐selectin, and sTREM2, suggesting strong association with proinflammatory glial response from neuronal injury (Figure 2D). PC5 was also associated with WMH volumes (*p<0.05, Figure 3A) and with CMH count in participants with CMH (**p<0.005, Figure 3B).ConclusionsThis PCA approach indicates that some groups of NVU‐associated proteins are related with mutation status and disease stage, and that they are differentially associated with features of ADAD such as white matter integrity as measured by WMH volume. Weighted Correlation Network Analysis will be of interest to further understand these associations. Funding: K01AG080123, RF1‐AG044546, UF1AG032438
Protective mechanism of APOE3‐Christchurch in Alzheimer’s disease
Alnobani, Alla, Crow, A. , Dacquel, Maxwell V., Martens, Yuka A. , Kanekiyo, Takahisa , Raulin, Ana‐Caroline , Linares, Cynthia , Roy, Bhaskar, Doss, Sydney V. , Kuchenbecker, Lindsey A. , Karch, Celeste M. , Liu, Chia‐Chen , Bu, Guojun

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S6 | Pages: No page available

10.1002/alz.093237 Get It

AbstractBackgroundHomozygosity for the rare APOE3‐Christchurch (APOE3Ch) variant, encoding for apoE3‐R136S (apoE3‐Ch), was linked to resistance against an aggressive form of familial Alzheimer’s disease (AD). Carrying two copies of APOE3Ch was sufficient to delay autosomal AD onset by 30 years. This remarkable protective effect makes it a strong candidate for uncovering new therapies against AD. Thus, we aim to explore the protective mechanisms of APOE3Ch against AD onset, to inform therapy.MethodsWe used both amyloid mouse models and human induced‐pluripotent stem cells (iPSC) models to address this aim. We examined whether astrocytic expression of apoE3‐Ch through an AAV‐mediated approach can mitigate AD‐related pathology and toxicity in early (3.5 months old) and late (8 months old) amyloid pathology in 5xFAD mice. We also used isogenic iPSC lines carrying the APOE3Ch variant that were generated from APOE3 parental lines using CRISPR/Cas9 technology. Biochemical and biophysical properties of both recombinant and native apoE3‐Ch lipoprotein particles secreted by iPSC‐derived astrocytes have been investigated using different techniques including heparin affinity chromatography and size‐exclusion chromatography.ResultsWe investigated the impact of astrocytic apoE3‐Ch on amyloid pathology and toxicity in 3.5‐month‐old and 8‐month‐old 5xFAD mice. We confirmed successful AAV‐mediated overexpression of apoE3 and apoE3‐Ch in astrocytes. We found apoE3‐Ch specific changes in protein levels and solubility. Astrocytic expression of apoE3‐Ch reduced soluble Aβ oligomer levels and ameliorated ER stress response compared to apoE3 in the 8‐month‐old 5xFAD mice. Furthermore, our findings showed altered biochemical properties of HEK cell‐derived apoE3‐Ch protein, including decreased heparin binding, altered receptor binding, and enhanced lipid accepting capacity. We also characterized APOE3Ch iPSC‐derived cell models, including iPSC‐derived astrocytes, neurons, and cerebral organoids, and found differences between APOE3 and APOE3Ch at the functional level in these iPSC models.ConclusionsThe proposed work and the developed methods to study apoE3‐Ch promises to provide new insights into the possible roles of this rare, mutated protein in protecting against AD, offering new therapeutic avenues for AD treatment.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Wei, Andrew H. , Marcucci, Guido , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Stelljes, Matthias , Najima, Yuho , Wei, Andrew H , Hill, Jason , Chen, Yi-Bin , Hamadani, Mehdi , Wingard, John R. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Hill, Jason E. , King, Denise, Devine, Steven M.

Mayo Clinic

Blood | January 7, 2025 | Volume: 145 | Issue: 19 | Pages: 2138-2148

10.1182/blood.2024025154 | PMID 39775763 Get It

Abstract BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mutated acute myeloid leukemia (AML). A key secondary end point was to determine the impact on survival of before and/or after HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD. We conducted a post hoc analysis of the data and found that the level of MRD detected with this approach correlated remarkably with RFS and relapse risk, and that MRD detectable at any level negatively affected RFS. In the placebo arm, 42.2% of participants with detectable FLT3-ITD MRD relapsed compared with 13.4% of those without detectable MRD. We found that 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. Finally, we examined the kinetics of FLT3-ITD clonal relapse or eradication and found that participants on the placebo arm with detectable MRD relapsed rapidly after HCT, often within a few weeks. MRD-positive participants on the gilteritinib arm relapsed either with FLT3 wild-type clones (assessed by capillary electrophoresis), after cessation of gilteritinib with persistent MRD, or on progression of multiclonal disease. These data demonstrate the potential of FLT3-ITD MRD to guide therapy with gilteritinib for this subtype of AML. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
Neuro-Ophthalmic Literature Review
Chen, John J. , Hung, Wei-Che , Vaphiades, Michael S., Chen, John J , Mak, Andrew C. Y. , Verma, Rashmi , Zhang, Xiaojun

Mayo Clinic

Neuro-Ophthalmology | January 7, 2025 | Volume: 49 | Issue: 1 | Pages: 105-110

10.1080/01658107.2024.2431470 Get It

Glucarpidase for treatment of high-dose methotrexate toxicity
Gupta, Shruti , Kaunfer, Sarah Allison , Chen, Kevin L. , Dias, Julie‐Alexia , Rajasekaran, Arun , Prosek, Jason, Truong, Huong L. , Wood, Anthony C., Bassil, Claude , Renaghan, Amanda D., Carlos, Christopher A., Kelly, Katherine J. , Passero, Christopher J., Abudayyeh, Ala , Shin, Daniel Sanghoon , Yelvington, Bradley, Kanduri, Swetha Rani , Neyra, Javier A. , Shirali, Anushree C. , Bansal, Anip, Geara, Abdallah Sassine , Mithani, Zain, Ziolkowski, Susan , Rashidi, Arash, Jakubowski, Jonathan, Pujari, Ashwini, Dotson, Emily, Wall, Sarah , Patton, John T. , Barreto, Jason N. , Sheikh, M. Salman , Lee, Jamie, Lucchesi, Nicholas, Kolman, Michael David, Rasheed, Muhammad Ahsan, Afzal, Afsheen, Mahesh, Amrita, Hsu, Raymond K. , Nicolaysen, Anthony, Tefera, Kibrewessen, Schretlen, Claire F. , Miller, Ryan M. , Velez, Juan Carlos Q. , Chandrasekhara, Soniya, Donley, Vicki, Patel, Ashka , Krishnamurthy, Shobana, Ali, Rafia, Yilmam, Osman A , Wells, Sophia L., Ortega, Jessica L. , Green‐Lingren, Olivia, Leaf, Rebecca Karp , Sise, Meghan E. , Nayak, Lakshmi , LaCasce, Ann S. , Leaf, David E. , Kaunfer, Sarah A , Rajasekaran, Arun , Shah, Chintan V , Glezerman, Ilya G , Kelly, Katherine , Abudayyeh, Ala , Neyra, Javier A , Edmonston, Daniel , Ziolkowski, Susan L , Bond, David A , Patton, John , Barreto, Jason N , Herrmann, Sandra M , Sheikh, Mohammad S , Hsu, Raymond K , Aklilu, Abinet M , Krishnamurthy, Shobana , Yilmam, Osman A , Ortega, Jessica L , LaCasce, Ann Steward , Leung, Nelson , Leaf, David E , Gupta, Shruti , Dias, Julie-Alexia , Vijayan, Anitha , Zhang, Jingjing , Drappatz, Jan , Sperati, Christopher John , Rashidi, Arash , Bond, David A. , Patton, John T. , Herrmann, Sandra M. , Baz, Rachid , Lee, Jamie, Kolman, M F , Afzal, Afsheen, Kang, Dasol, Mahesh, Amrita, Miller, Ryan M., Flannery, Alexander H , Aklilu, Abinet M. , Anand, Shuchi , Ni, Jian, Wells, Sophia L., Leung, Nelson

Mayo Clinic

Blood | January 6, 2025 | Volume: 145 | Issue: 17 | Pages: 1858-1869

10.1182/blood.2024026211 | PMID 39760780 Get It

Abstract High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but clinical data supporting its use are scarce. We examined the association between glucarpidase administration and outcomes in adults with MTX-AKI from 28 cancer centers across the United States using a sequential target trial emulation framework. The primary end point was kidney recovery at hospital discharge, defined as survival to discharge with serum creatinine &lt;1.5-fold baseline and without dialysis dependence. Key secondary end points were time to kidney recovery, neutropenia, and transaminitis on day 7, and time to death. Using multivariable logistic and Cox regression models, we compared outcomes in patients who received glucarpidase within 4 days following MTX initiation with those in patients who did not. Among 708 patients with MTX-AKI, 209 (29.5%) received glucarpidase. Overall, 183 (25.8%) had a primary end point event. Glucarpidase receipt was associated with a 2.70-fold higher adjusted odds of kidney recovery (95% confidence interval [CI], 1.69–4.31) compared with no glucarpidase receipt. Patients treated with glucarpidase also had faster time to kidney recovery (adjusted hazard ratio [aHR], 1.88; 95% CI, 1.18–3.33) and lower risks of grade ≥2 neutropenia (adjusted odds ratio [aOR], 0.50; 95% CI, 0.28–0.91) and grade ≥2 transaminitis (aOR, 0.50; 95% CI, 0.28–0.91) on day 7. There was no difference in time to death (aHR, 0.76; 95% CI, 0.49–1.18). These data suggest glucarpidase may improve both renal and extrarenal outcomes in patients with MTX-AKI.
Towards H&E Referenced Multiplex Immunofluorescence Interpretation: Spatial Co-localization, Cell Feature Validation, and Virtual H&E Generation
Wang, Chen , Moore, Raymond M. , Novotny, Brenna C. , Guo, Ruifeng , Fogarty, Zachary C. , Liu, Yuanhang , Goode, Ellen L. , Winham, Stacey J. , Markovic, Svetomir N. , Jiang, Jun , Novotny, Brenna , Guo, Ruifeng , Fogarty, Zachary C , Goode, Ellen L , Winham, Stacey J , Markovic, Svetomir , Wang, Chen , Jiang, Jun

Mayo Clinic

No container title available | January 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5619126/v1 | PMID 39866878 Get It

Abstract Multiplexed Immunofluorescence (MxIF) enables detailed immune cell phenotyping, providing critical insights into cell behavior within the tumor immune microenvironment (TIME). However, signal integrity can be compromised due to the complex cyclic staining processes inherent to MxIF. Hematoxylin and Eosin (H&E) staining, on the other hand, offers complementary information through its depiction of cell morphology and texture patterns and is often visually cross-referenced with MxIF in clinical settings. In this study, we proposed a novel framework to align H&E and MxIF images for precise cross-modal cell feature validation. Using cell detection outputs from each modality as anchors, we formulated the multimodal image registration problem as point set alignment. Coherent Point Drift (CPD) is employed for initial alignment, followed by Graph Matching (GM) for refinement. Evaluations on ovarian cancer tissue microarrays (TMAs) demonstrate that our method achieves high alignment accuracy, enabling reliable validation of cell-level features across modalities for both restained and serial sections. Our results indicate that restained H&E enhances confidence in findings derived from MxIF. Additionally, we demonstrated the feasibility of generating high-quality virtual H&E images from MxIF data when restained H&E is unavailable, offering a viable alternative for integrated multimodal analysis.
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
Young, Ken H. , Jia, Youchao, Tzankov, Alexandar , Go, Heounjeong , Li, Ling , Zhai, Qiong-Li , Perry, Anamarija M. , Wang, Shi , Wang, Xiaoxiao , Chiu, April , Xu, Mina L. , Visco, Carlo , Yuan, Alyssa F. , Miao, Yi , Li, Jianyong , Shuai, Wen , Wang, Bangchen , Pan, Zenggang , Chen, Weina , Zhang, Shanxiang , Sohani, Aliyah R. , Ferreri, Andrés J.M. , Xu, Bing , Young, Ken H , Tzankov, Alexandar , Go, Heounjeong , Xu, Mina , Dybkaer, Karen , Withers, Henry , Li, Jianyong , Bhagat, Govind , Chen, Weina , Møller, Michael Boe , Zhan, Fenghuang , Sohani, Aliyah , Ferreri, Andrés J M , Xu, Bing , Li, Yong , Wang, Bangchen , Shi, Wenyu , Xu‐Monette, Zijun Y. , Ponzoni, Maurilio , Wang, Yafei , Dybkær, Karen , Long, Mark D. , Macias, Everardo , Bhagat, Govind , Zu, Youli , Choi, William, Montes‐Moreno, Santiago , Krieken, J. Han van , Møller, Michael , Zhan, Fenghuang , Parsons, Benjamin M. , Hsi, Eric D. , Abramson, Jeremy S. , Li, Yong

Mayo Clinic

No container title available | January 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5732026/v1 | PMID 39866884 Get It

Abstract Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive lymphoma with molecular heterogeneity not well characterize. In this study, we performed next-generation sequencing analysis for a large number of DNA and RNA samples from patients with PT-DLBCL. DNA sequencing analysis identified ≥ 3 chromosomes with copy number variations (CNVs) and microsatellite instability as prognostic biomarkers, rather than MYD88 mutations and genetic subtypes. Remarkably, targeted RNA-seq analysis in 195 patients revealed that TP53 mutations with a ≥ 40% variant allele frequency had significantly adverse prognostic impact, and that a 150-gene expression signature subdivided PT-DLBCL into two distinct clusters, termed as testicular lymphoma tumor (TLT) and microenvironment (ME) subtypes. The TLT subtype featured upregulation of genes involved in B-cell receptor signaling, cell cycle, DNA damage and repair, higher frequencies of CNVs and MYD88 mutations, elder ages, larger tumor sizes, and significantly poorer survival. Genomic microRNA profiling analysis identified significantly differentially expressed microRNAs between 113 PT-DLBCL and 180 systemic DLBCL patients, and further subdivided the PT-DLBCL cohort by microRNA signatures. The subcohort with upregulation of 16 microRNAs associated with PT-DLBCL and testicular tissue expression had significantly better survival. This study revealed characteristic genetic, gene expression, and microRNA profiles and heterogeneity in PT-DLBCL.
Postanesthesia Sling Lift Transfer and Upright Extubation of an Adult Secured in a Motorized Wheelchair: A Case Report
Ellis, Megan , Chen, James L. , Ellis, Megan M

Mayo Clinic

A&A Practice | January 6, 2025 | Volume: 19 | Issue: 1 | Pages: e01901

10.1213/xaa.0000000000001901 | PMID 39760413 Get It

This case report describes a 29-year-old patient with cerebral palsy whose mother, for safety reasons, requested that before extubation in the postanesthesia care unit, her son be transferred from the padded stretcher to his personal motorized wheelchair. Using a sling lift, we safely transferred the anesthetized, intubated patient from a supine position to an upright sitting position. Although sling lifts are often used in critical care and rehabilitation environments, use in the perioperative space is rare. In this case report, we demonstrate how a sling lift can enhance safety for patients and perioperative staff.
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3‐dependent necroptotic inflammation
Wu, Zheming , Xiao, Huaping, Ouyang, Yaobin , Yin, Ping , Huang, Jinzhou , Lu, Jing , Tu, Xinyi , Ting, Adrian T. , Welliver, M.X., Lou, ZhenkunLou, Zhu, Shouhai , Dragojevic, Sonja , Lou, Zhenkun , Welliver, Meng, Kloeber, Jake A. , Chen, Bin, Han, Yiqun

Mayo Clinic

Cancer Communications | January 4, 2025 | Volume: 45 | Issue: 4 | Pages: 406-410

10.1002/cac2.12648 | PMID 39754711 Get It

Preserved transcriptional networks in immune signaling pathways associated with chronic disease identified in Alzheimer’s disease and Parkinson’s disease, cross‐tissue analysis
Strickland, Samantha L. , Tsai, Wei, Chen, Xuan , Cherukuri, Yesesri , Allen, Mariet , Quicksall, Zachary , Wang, Xue , Carrasquillo, Minerva M. , Nho, Kwangsik, Petersen, Ronald C., Reddy, Joseph S. , Ertekin‐Taner, Nilüfer , Kantarci, Kejal , Carrasquillo, Minerva M. , Saykin, Andrew J. , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.092349 Get It

AbstractBackgroundSystemic inflammation plays a pivotal role in many chronic diseases including Alzheimer’s disease (AD). Assessing the composition of immune pathways in neurodegenerative diseases can contribute to precision medicine. Using publicly available transcriptomic data, we sought to elucidate transcriptional networks pertinent to inflammatory pathways across brain regions and peripheral blood in AD/mild cognitive impairment (MCI) and peripheral blood in Parkinson’s disease (PD).MethodFor the AD/MCI vs. control dataset, we analyzed bulk‐RNAseq collected from 6 brain regions of donors from ROSMAP, Mayo Clinic, and Mount Sinai School of Medicine (MSSM) brain banks available from the AMP‐AD consortium. Ante‐mortem, blood RNAseq expression data was retrieved from the AMP‐AD Emory Vascular cohort and Mayo Clinic Study of Aging (MCSA). We also collected blood‐derived microarray expression data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). For the PD vs Control dataset, blood‐derived bulk‐RNAseq from the PDBP and PPMI cohorts were available through the AMP‐PD consortium. Following quality control, normalization, and residual generation to account for biological and technical variables, co‐expression network modules and their enriched pathways were identified using WGCNA within each dataset. Module/trait correlation tests for aging and diagnosis (cases [AD/MCI or PD] vs control) phenotypes were evaluated. Gene Ontology enrichment analyses were executed to identify enriched pathways and brain or blood cell types within the modules. Modules were tested for preservation across cohorts.ResultWe identified conserved immune signatures across brain regions and cohorts. Modules involved in immune response were preserved across all cohorts. Blood consensus modules involved in immune response were preserved in the brain and vice versa. Some immune modules were associated with AD/MCI, PD, and/or aging. Brain immune modules are significantly associated with aging and/or AD. Significant correlations (q<0.05) with PD diagnosis were present. In the MCSA and Emory vascular cohorts, there were no significant (q<0.05) associations between modules and diagnosis, while in ADNI there were nominal (p<0.05) associations.ConclusionPreserved transcriptional immune networks were identified across blood and brain and across two neurodegenerative diseases. Expanding gene co‐expression network analyses to other diseases and integrating additional omics measures and phenotypes can further strengthen these findings to unravel the immune signatures across complex diseases.